Table 1 Demographics and baseline disease characteristics
|  | Total (N = 57) |
|---|---|
Age, n (%) | |
 < 65 | 46 (81) |
 ≥ 65 | 11 (19) |
 Mean (SD) | 55 (9) |
 Median (range) | 54 (27 to 72) |
Sex, n (%) | |
 Male | 34 (60) |
 Female | 23 (40) |
ECOG performance status, n (%) | |
 0 | 21 (37) |
 1 | 27 (47) |
 2 | 9 (16) |
ISS stage, n (%) | |
 I | 15 (26) |
 II | 14 (25) |
 III | 21 (37) |
 Unknown | 7 (12) |
Type of myelomaa, n (%) | |
 IgG | 25 (44) |
 IgA | 15 (26) |
 Light chain | 17 (30) |
  Kappa | 7 (12) |
  Lambda | 10 (18) |
Time from initial MM diagnosis, years | |
 Mean (SD) | 4 (2) |
 Median (range) | 4 (1 to 9) |
Number of prior lines of therapy, n | |
 Mean (SD) | 3 (2) |
 Median (range) | 3 (1 to 9) |
Autologous stem cell transplantation, n (%) | 10 (18) |
Prior therapies, n (%) | |
 Proteasome inhibitors | 39 (68) |
  Bortezomib | 39 (68) |
  Carfilzomib | 1 (2) |
 Immunomodulatory agents | 49 (86) |
  Lenalidomide | 25 (44) |
  Pomalidomide | 2 (4) |
  Thalidomide | 39 (68) |
 Proteasome inhibitors + immunomodulatory agents | 34 (60) |